Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Belite Bio, Inc. ADR ( (BLTE) ) has provided an update.
Belite Bio, Inc announced its financial results for the fourth quarter and full year of 2024, alongside a corporate update. The company highlighted the progress of its Phase 3 DRAGON trial for Stargardt disease, which received a positive recommendation from the Data Safety Monitoring Board to continue without modifications. Additionally, the company raised $15 million in a direct offering in February 2025, bolstering its financial position to advance its clinical trials. The company’s financial results showed an increase in research and development expenses, attributed to share-based compensation and trial milestones, while reporting a net loss of $36.1 million for 2024.
More about Belite Bio, Inc. ADR
Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.
YTD Price Performance: 4.15%
Average Trading Volume: 44,650
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.08B
See more data about BLTE stock on TipRanks’ Stock Analysis page.